In this Application Note we discuss:
More about this Application Note
Checkpoint inhibitor blockade therapy has rapidly advanced and is now established as a powerful way to manage various malignant tumors.
Despite the promising outcomes, there are a significant number of patients who do not respond to these immunotherapies.
Download this App Note to learn how IsoPlexis’ PSI helps you overcome these challenges with a wide range of applications in checkpoint and combination therapy research.